Cardiol Therapeutics Inc. (FRA:CT9)

Market Cap	88.12M -7.0%
Revenue (ttm)	n/a
Net Income	-21.28M
EPS	-0.26
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.8100
Previous Close	0.8180
Day's Range	0.8100 - 0.8100
52-Week Range	0.6000 - 1.3800
Beta	n/a
RSI	42.88
Earnings Date	Mar 27, 2026

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical develop...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 18
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CT9

Financial Performance

Financial numbers in CAD